ALKERMES | ALKS - Srodki Pieniężne I Ekwiwalent

Cena Akcji
33.31
Dzienna Zmiana
-0.60 -1.77%
Miesięcznie
13.42%
Rocznie
19.65%
Q2 Prognozy TE
32.32




Srodki Pieniężne I Ekwiwalent Zmiana Data
AbbVie USD 5.23B 400M 2025-12
Acadia Pharmaceuticals USD 819.69M 27.33M 2025-12
ALKERMES USD 388.57M 227.88M 2025-12
Amgen USD 9.13B 316M 2025-12
Biogen USD 3.01B 854.3M 2025-12
BioMarin Pharmaceutical USD 1.31B 61.57M 2025-12
Bristol-Myers Squibb USD 10.21B 5.52B 2025-12
Coherus Biosciences USD 88.88M 14.47M 2025-12
Eli Lilly USD 7.27B 2.52B 2025-12
Gilead Sciences USD 7.56B 234M 2025-12
Heron Therapeutics USD 43.07M 26.55M 2025-09
Ionis Pharmaceuticals USD 2.68B 437M 2025-12
J&J USD 21.69B 1.98B 2026-03
Malin Corporation EUR 62.1M 26.4M 2024-12
Merck USD 18.17B 10.16B 2025-09
Minerva Neurosciences USD 82.3M 70.02M 2025-12
Nektar Therapeutics USD 15.12M 25.92M 2025-12
Neurocrine Biosciences USD 713M 372.8M 2025-12
Otsuka Holdings JPY 411.11B 3.62B 2025-06
Pfizer USD 1.34B 295M 2025-09
Regeneron Pharmaceuticals USD 18.87B 16.36B 2025-12
Vertex Pharmaceuticals USD 6.61B 321.1M 2025-12